Table 2 Stepwise optimization of amount of drug and solid lipid-to-liquid lipid ratio
From: Nanolipid carrier-based thermoreversible gel for localized delivery of docetaxel to breast cancer
Step | Formulation code | Variable parameters | Response parameters | Opt. parameter | Level of Opt (code) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solid lipid (mg)/liquid lipid | Pluronic F68 (mg) | Drug Conc. (mg) | Homogenization time (min) | Sonication time (min) | Size range in nm (Opta) | PDI range (Opta) | Entrapment | Zeta potential (mV) | ||||
Step 4 | F16–F19 | 200 | 200 | 7.5–12.5 | 3 | 4 | 248–108.7 (123.5 ± 18.45) | 0.248–0.210 (0.218 ±0.014) | 70–80 (80 % ± 2.645) | – | Drug amount | 10 mg (F17) |
Step 5 | F20 to F23 | 170:30 to 110:90 | 200 | 10 | 3 | 4 | 135 to 118.7 (118.7 ± 5.42) | 0.266 to 0.214 (0.250 ± 0.034) | 75–85 (85 % ± 3) | −33.44 to −31.57 (−33.44 ± 2.54) | Solid lipid/liquid lipid | 170:30 (F21) |